Profile of IHC Marker in Lung Tumours

  • Aparna Bhardwaj SGRR Institute of Medical & Health Sciences, Patel Nagar, Dehradun
  • Snigdha Petwal SGRR Institute of Medical & Health Sciences, Patel Nagar, Dehradun
  • Rajnish Kumar SGRR Institute of Medical & Health Sciences, Patel Nagar, Dehradun
  • Sanjay Kaushik SGRR Institute of Medical & Health Sciences, Patel Nagar, Dehradun
  • Sanjeev Kishore All India Institute of Medical Science, Rishikesh, India
Keywords: Adenocarcinoma, CK5/6, Immunohistochemistry, Squamous cell carcinoma, TTF-1


Background: Lung biopsy is crucial in histopathological subtyping and classification. However, making an accurate diagnosis in small biopsies can be challenging. This study was aimed to distinguish and classify lung tumors employing immunohistochemical markers TTF-1(thyroid transcription factor 1), Cytokeratin 5/6, Cytokeratin 20, AE1/3. Subsequently, prognostic value of different histological types of lung tumours was established employing Ki-67.   Material & Methods A total of 52 clinically diagnosed cases of lung carcinoma over a period of two years were included in our study. Of these 2 cases were excluded from the study as they showed granulomas on histopathology. All the cases after being diagnosed on H&E were subjected to Immunohistochemistry (IHC). Statistical Analysis: The statistical analysis was done using SPSS for Windows 15.0 program. Specificity, sensitivity, positive predictive value, negative predictive value of all these IHC markers was statistically evaluated.   Results Of 29 cases diagnosed as Squamous cell carcinoma (SCC) on H&E, 26 were CK5/6 positive on IHC. Of 4 cases diagnosed as Primary Adenocarcinoma (ADC) on H&E, 3 were TTF-1 positive. Four cases of poorly differentiated carcinoma diagnosed on H&E, 1 case was diagnosed as SCC and 2 cases as Metastatic ADC on IHC. Ki-67 was high in 82.8% cases of SCC and in 50% cases of ADC. The sensitivity and specificity of CK5/6 and TTF-1 was 100%, 57.1% and 100%, 96.7% respectively.   Conclusion: Employing IHC markers either singly or in a panel is a useful adjunct to morphological features and clinical parameter in the diagnosis and management of lung tumour.

Author Biographies

Aparna Bhardwaj, SGRR Institute of Medical & Health Sciences, Patel Nagar, Dehradun
Department of Pathology, Professor
Snigdha Petwal, SGRR Institute of Medical & Health Sciences, Patel Nagar, Dehradun
Department of Pathology
Rajnish Kumar, SGRR Institute of Medical & Health Sciences, Patel Nagar, Dehradun
Department of Pathology
Sanjay Kaushik, SGRR Institute of Medical & Health Sciences, Patel Nagar, Dehradun
Department of Pathology
Sanjeev Kishore, All India Institute of Medical Science, Rishikesh, India
Department of Pathology


1. Edges SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17(6):1471-4.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics,2014.CA: a cancer journal for clinicians 2014;64(1):9-29.
3. Indian council of Medical Research;2013. National Cancer Registry Programme. Three year report of Population Based Cancer Registries:2009-11.
4. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geising KR, Yatabe Y et al. International association for the study of lung cancer/American thoracic society/ European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6(2):244-85.
5. Travis WD, Harris Cc. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Feance: IARC Press,2004;2004.
6. Grilley-Olson JE, Hayes DN, Moore DT, Lesile Ko, Wilkerson MD, Qaqish BF et al. Validation of Interobserver Agreement in Lung Cancer Assesment: Hematoxylin-Eosin Diagnostic Reproducibility for Non- Small Cell Lung Cancer: The 2004World Health Organisation Classification and Therapeutically Relevant Subsets. Arch Pathol Lab Med 2012; 137(1):32-40.
7. Bishop JA, Sharma R, Illegi PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid and malignant mesothelioma. Hum Pathol. 2010;4191):20-25.
8. Carvalho L. Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Revista Portuguesa Pneumologia (English Edition)2009; 15(6):1101-19.
9. Munfus –McCray D, Cui M, Zhang Z, Gabrielson Askin F, Li QK. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. Hum Pathol 2013;44(7):1286-92.
10. Yang P,Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjeji AA et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. CHEST Journal. 2005;128(1):452-62.
11. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens . Modern Pathology. 2011;24(10):1348
12. Whithaus K, Fukuoka J, Prihoda TJ, Jagirdar J: Evaluation of napsin A, Cytokeratin 5/6, p63 and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med.136:155-62,2012.
13. Yanagita E, Imagawa N, Ohbayaschi C, Itoh T: Rapid multiplex immunohistochemistry using the 4-antibody cocktail YANA-4in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung. Appl. Immunohistochem Mol Morphol. 19 :509-13;2011.
14. Rossi G, Pelosi G, Giaziano Pet al. A reevaluation of the clinical significance of histological subtyping of non-small cell lung carcinomas: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009;17:206-18.
15. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch. Pathol Lab Med 2008;132(3):384-96.
16. Su YC, Hsu YC, Chai CY. Role f TTF-1, CK-20 and CK7 Immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsung J Med Sci.2006;22(1):14-9.
17. Kangi A, Gurel D, Tuna B. The diagnostic value of TTf-1, CK5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol. Morphol.2007;15:415-20.
18. Khayyata S, Yun S, Pasha T et al. Value of p63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol.2009;37:178-83.
19. Ng WK, Chow JC, Ng PK: Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion cytology specimens. Cancer 2002;96:43-48.
20. Yatabe Y, Mitsudomi J, TakahashiT: TTF-1 expression in pulmonary adenocarcinoma. Am J Surg Pathol.2002;26:763-73.
21. Ocque R, Tochigi N, Ohori P, Dacie S et al. Usefulness of Immunohistochemical and Histochemical Studies in classification of lung adenocarcinoma and Squamous cell carcinoma in Cytologic Specimens. Am J Clin Pathol.2016;136:81-87.
22. Jorda H, Gomez-Fernandez C, Garcia M et al. p63 differentiates subtypes of non small-cell carcinoma of lung in cytologic samples: implications in treatment selection. Cancer 2009:117;46-50.
23. Shibuki Y, Tsula K, Nomoto K et al: Immunocytochemical study of specific immunohistochemical markers for primary lung. J Jpn Clin Cytol2007; 46:120-21.
24. Miyarchi E, Motoi N, Ono H, Ninomya h, Ohyaanay F et al. Distinct charactersticks of small cell lung cancer correlate with central or peripheral origin: subtyping basal on location and expression of transcription factor TTF-1. Medicine 2015, 94(51)…..
25. Kapila K, Al-Ayadhy B, Francis IM, George SS, Al-Jassar A. Subclassification of pulmonary non-small cell lung carcinoma in fine needle aspirates using a limited immunohistochemistry panel. J Cytol. 2013 Oct-Dec; 30(4): 223–225
26. Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC et al. Utility of five commonly used immunohistochemical markers TTF-1< Napsin A, CK7, CK5/6 and p63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clinical and translational medicine.2015Apr21;4(1):16.
Original Article